The general recurrence risk of Angelman syndrome in the general population is less than 1%. Families previously identified with a genetic anomaly can consider prenatal diagnostic methods. In specific cases where the familial transmission risk is high (such as chromosomal anomalies and rearrangements, imprinting defects, or UBE3A gene point mutations), it is possible to prevent Angelman syndrome through in vitro fertilization treatment by selecting genetically healthy embryos using Preimplantation Genetic Diagnosis - Molecular (PGT-M).